Pleneva

[scoobyjude]

BTG Commences Phase IIa Study Of Pleneva For Multiple Sclerosis - Quick Facts
1/21/2010 2:51 AM ET


(RTTNews) - BTG Plc (BGC.L: News ) said it commenced dosing in a European multicentre Phase IIa study of Pleneva, a novel orally administered compound under development as a potential treatment for multiple sclerosis.

According to the company, the study, in 166 patients with the relapsing-remitting form of the disease, comprises an initial 24 week double-blind, placebo-controlled dosing period followed by a 24 week open-label extension. The primary endpoint of the study is a reduction in the number of new T1 gadolinium enhanced lesions on MRI at weeks 12, 16, 20 and 24 when compared to placebo.

[CureOrBust]

http://www.btgplc.com/DevelopmentPipeli ... 00134.html

In a small single-centre, double-blind, placebo-controlled clinical pilot study, an experimental Pleneva™ prototype provided clinical benefits to patients with RRMS, including decreases in both relapse rate and EDSS scores, with additional benefits seen on pain and cognitive endpoints.

Now I'm interested.

[scorpion]

The reduction in EDSS score got my attention as well!!! Nice find scoobyjude.

[dignan]

Thanks for the update scooby. I've got it in the pipeline under its old, less catchy name, BGC20-0134.

[Suchislife]

Do we know if this drug made it or not??? Is it in another phase?? I can see it has been awhile, but I am interested. I'm searching through the forum, but I can't seem to find it... Help if you can.
Thanks!

[arabia]

BTG Commences Phase IIa Study Of Pleneva For Multiple Sclerosis - Quick Facts
1/21/2010 2:51 AM ET


(RTTNews) - BTG Plc (BGC.L: News ) said it commenced dosing in a European multicentre Phase IIa study of Pleneva, a novel orally administered compound under development as a potential treatment for multiple sclerosis

According to the company, the study, in 166 patients with the relapsing-remitting form of the disease, comprises an initial 24 week double-blind, placebo-controlled dosing period followed by a 24 week open-label extension. The primary endpoint of the study is a reduction in the number of new T1 gadolinium enhanced lesions on MRI at weeks 12, 16, 20 and 24 when compared to placebo.

any update ? please

[DougL]

any update ? please

from the manufacturers web site

BGC20-0134 (Pleneva™) did not meet its primary or secondary endpoints in a six-month double-blind placebo-controlled Phase IIa study in patients with relapsing remitting multiple sclerosis. Data from approximately 65% of patients who have completed an optional six-month open-label study extension will be analysed to determine if any treatment effects are evident at 12 months that were not found after 6 months.